Skip to main content
. 2021 Jan 27;10:e62586. doi: 10.7554/eLife.62586

Figure 2. Lymphoblastoid cell lines (LCLs) exhibit anticorrelated expression gradients of activation and differentiation genes.

(A) Inverse expression gradients of immunoglobulin genes (IGHM, IGHA1, and IGHG1) in magenta and NFκB targets (NFKB2, NFKBIA, EBI3, ICAM1, and BCL2A1) and TXN in green. (B) Similar inverse gradients of NFκB targets in green and B cell differentiation markers (TNFRSF17, XBP1, MZB1, CD27, and CD38) in orange. (C) Pearson correlation maps and hierarchical clustering reveal negative correlation of differentiation (orange) and activation (green) gene sets and positive correlations between genes within each set. (D) In LCLs comprising multiple immunoglobulin isotypes, heavy chain class and differentiation/activation gradients constitute orthogonal (independent) axes of phenotypic variance.

Figure 2.

Figure 2—figure supplement 1. Expression of individual genes within activation and differentiation gene sets.

Figure 2—figure supplement 1.

(A) Expression of genes involved in activation/pro-survival of B cells. (B) Expression of genes involved in B cell differentiation. (C) Correlation of each activation and differentiation gene with IgG1 expression for GM18502 (a sample with a single isotype class).
Figure 2—figure supplement 2. Expression of metabolic and oxidative stress genes.

Figure 2—figure supplement 2.

Figure 2—figure supplement 3. Expression of NF-κB subunits c-REL, RELA, and RELB.

Figure 2—figure supplement 3.

Figure 2—figure supplement 4. Expression of BCL2 family genes across lymphoblastoid cell line (LCL) samples.

Figure 2—figure supplement 4.

Figure 2—figure supplement 5. Expression trends in key transcriptional regulators controlling activated B cell (ABC) and antibody-secreting cell (ASC) phenotypes.

Figure 2—figure supplement 5.

Figure 2—figure supplement 6. Expression of host targets upregulated by EBNA2.

Figure 2—figure supplement 6.

Figure 2—figure supplement 7. Expression of host targets repressed by EBNA3.

Figure 2—figure supplement 7.

Figure 2—figure supplement 8. Cell proliferation and metabolic profiling by ICAM expression.

Figure 2—figure supplement 8.

(A) Averaged (top-left panel) and individual lymphoblastoid cell line (LCL) growth rates in sorted ICAM-hi (teal) and ICAM-lo (sienna) fractions. (B) Metabolic profiling of ICAM-hi and ICAM-lo fractions of LCLs.